PeptideWiki

Are peptides legal? The US legal categories for peptides in 2026, explained

Published by the PeptideWiki editorial team.

BPC-157 TB-500 KPV MOTS-c Semax Epitalon Tirzepatide

Are peptides legal? It depends on the box: FDA-approved drugs, 503A compounding under the October 2026 HHS policy, research-use-only products, and the WADA Prohibited List.

Are peptides legal? In the US, there is no single answer, because "peptide" is a chemical class, not a legal one. A peptide's status depends on which regulatory box it sits in. Some are FDA-approved drugs. Some can be compounded by pharmacies under conditions. Many are unapproved substances sold with "research use only" labels. Sport has its own separate rules.

This explainer sorts peptides into those boxes as of November 2026. It describes the rules, not how to use any compound. It is not legal advice.

Are peptides legal as approved drugs?

The clearest category is FDA approval. An approved peptide drug has passed review for a specific use and is sold by prescription under its labeling.

Tirzepatide is an example. FDA approved it as Zepbound on November 8, 2023, for chronic weight management in adults meeting set BMI criteria. It was already approved as Mounjaro for type 2 diabetes. See the semaglutide vs tirzepatide vs retatrutide comparison for how the incretin-class compounds compare.

Approval covers the approved product. It does not make every copy of the same molecule legal to sell.

Compounding: the 503A rules and the bulks list

Compounding is the second box. A pharmacy prepares a drug for a specific patient under a prescription. Our 503A vs 503B guide explains the two pathways.

Under section 503A, FDA says a pharmacy may only use bulk drug substances that meet one of three conditions:

  1. They comply with a USP or NF monograph, if one exists.
  2. They are components of an FDA-approved drug, if no monograph exists.
  3. They appear on the 503A bulks list, if neither of the above applies.

Most research peptides meet none of these. They have no monograph, are not in an approved drug and are not on the list. While FDA reviews nominations, it sorts them into interim categories. Category 1 substances may be used under an enforcement policy. Category 2 covers substances where FDA "has identified significant safety risks." Category 3 covers nominations with insufficient supporting information.

FDA's category 2 page lists several peptides. GHRP-2, GHRP-6 and ipamorelin acetate sit in active category 2 for 503B. Kisspeptin-10 is listed for 503A. A longer group of peptides once in category 2 was withdrawn by the nominators. It includes BPC-157, TB-500, KPV, MOTS-c, epitalon, semax, selank, CJC-1295, AOD-9604, thymosin alpha-1 and melanotan II.

FDA's stated concerns were specific. For several peptides it cited possible immunogenicity "due to the potential for aggregation and peptide-related impurities." For BPC-157 it said it had found "no, or only limited, safety-related information." For KPV, MOTS-c and the TB-500 fragment it said it had not identified any human exposure data.

The October 2026 HHS interim policy

In late October 2026, HHS issued an interim enforcement discretion policy for six peptides: BPC-157, epitalon, KPV, MOTS-c, semax and TB-500. It followed a July 2026 advisory committee vote backing them for the 503A bulks list. Our earlier post covers the policy in detail.

The key points for the legal question:

  • It covers "a State-licensed pharmacy, Federal facility, or licensed physician." Outsourcing facilities under 503B are not named.
  • HHS "does not intend to take enforcement action" only when ten listed conditions are met.
  • Conditions include a 510-registered, CGMP-compliant manufacturer, a valid certificate of analysis, adverse event reporting to FDA, and a patient-specific prescription.
  • Products must carry the label "This is a compounded drug product. Not for resale."
  • It lasts until FDA addresses each peptide in a final rule, and HHS may revisit it if safety or quality signals appear.

The policy is not an approval. The policy text itself notes that "Compounded drugs are not FDA-approved." Adding the peptides to the bulks list still requires rulemaking, and RAPS reported no timeline for it.

What "research use only" means legally

The third box is the gray market. Many peptides are sold as research chemicals labeled "not for human consumption." That label describes an intended use. It does not make a product an approved drug or a lawful compounding ingredient.

The HHS policy states its own aim plainly. It is meant to "discourage the continued, widespread use of certain research-use-only peptides supplied by foreign manufacturers." It does not extend to research-use-only products.

FDA has acted on this market before. A January 2026 Health Law Alliance review describes September 2025 warning letters over research-use-only peptide marketing, including BPC-157. STAT reported in February 2026 that FDA treats BPC-157 and some other peptides as unapproved drugs. It also noted that nearly all BPC-157 research was done in animals, so human evidence is very limited.

Quality is a separate concern in this market. Our guide on how to read a COA covers what testing documents can and cannot show.

Peptides in sport: the WADA Prohibited List

Anti-doping rules work independently of FDA status. A peptide can be legal to prescribe and still banned in competition.

The 2026 WADA list bans S0 "non-approved substances" at all times. That class covers drugs with no current approval for human therapeutic use, and it names BPC-157 as an example. Class S2 bans peptide hormones, growth factors and mimetics at all times. It names CJC-1295, sermorelin, tesamorelin, ipamorelin, GHRP-2, GHRP-6, hexarelin and "Thymosin-β4 and its derivatives, e.g. TB-500." Many of these sit in our GH-axis category.

WADA published the 2027 list in early October 2026. It enters into force on January 1, 2027. Announcements said the status of GLP-1 receptor agonists, including semaglutide and tirzepatide, remains unchanged. WADA said there was not yet enough evidence to conclude they meet its criteria.

The categories side by side

CategoryExample peptidesLegal basisKey limit
FDA-approved drugTirzepatide (Zepbound, Mounjaro)FDA approvalApproved product and labeling only
503A compounding, HHS interim policyBPC-157, TB-500, KPV, MOTS-c, epitalon, semaxEnforcement discretion, October 2026Ten conditions, prescription, until final rule
FDA category 2GHRP-2, GHRP-6, ipamorelin, kisspeptin-10Interim bulks policySafety risks identified; no category 1 protection
Research use onlyMany unapproved peptidesNo approval or compounding basisNot for human use; FDA warning letters issued
Sport (WADA)BPC-157 (S0), TB-500 and GH secretagogues (S2)Prohibited ListBanned at all times for tested athletes

Rules are moving quickly in this area. The PeptideWiki regulatory tracker logs new FDA, HHS and WADA actions as they happen.

Sources

  1. HHS: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (October 2026)
  2. FDA: Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (May 14, 2026)
  3. FDA: Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (April 22, 2026)
  4. FDA: FDA Approves New Medication for Chronic Weight Management (November 8, 2023)
  5. RAPS Regulatory Focus: HHS will permit compounding of six peptides ahead of formal rulemaking (October 29, 2026)
  6. Health Law Alliance: FDA Targets GLP-1 and Peptide Compounding, Advertising and 'Research Use Only' Labeling (January 8, 2026)
  7. STAT: From Croatia to MAHA: How an unapproved drug became the next hot peptide (February 3, 2026)
  8. FINCIS (Finnish Center for Integrity in Sports): Doping agent classes and substances 2026
  9. World Rugby: WADA publishes 2027 Prohibited List (October 6, 2026)

Educational content only, not medical advice. Compounds discussed as research materials are for laboratory research use only and are not for human or veterinary use.

More from the blog